Glycemic control and excess mortality in type 1 diabetes
- PMID: 25409370
- DOI: 10.1056/NEJMoa1408214
Glycemic control and excess mortality in type 1 diabetes
Abstract
Background: The excess risk of death from any cause and of death from cardiovascular causes is unknown among patients with type 1 diabetes and various levels of glycemic control. We conducted a registry-based observational study to determine the excess risk of death according to the level of glycemic control in a Swedish population of patients with diabetes.
Methods: We included in our study patients with type 1 diabetes registered in the Swedish National Diabetes Register after January 1, 1998. For each patient, five controls were randomly selected from the general population and matched according to age, sex, and county. Patients and controls were followed until December 31, 2011, through the Swedish Register for Cause-Specific Mortality.
Results: The mean age of the patients with diabetes and the controls at baseline was 35.8 and 35.7 years, respectively, and 45.1% of the participants in each group were women. The mean follow-up in the diabetes and control groups was 8.0 and 8.3 years, respectively. Overall, 2701 of 33,915 patients with diabetes (8.0%) died, as compared with 4835 of 169,249 controls (2.9%) (adjusted hazard ratio, 3.52; 95% confidence interval [CI], 3.06 to 4.04); the corresponding rates of death from cardiovascular causes were 2.7% and 0.9% (adjusted hazard ratio, 4.60; 95% CI, 3.47 to 6.10). The multivariable-adjusted hazard ratios for death from any cause according to the glycated hemoglobin level for patients with diabetes as compared with controls were 2.36 (95% CI, 1.97 to 2.83) for a glycated hemoglobin level of 6.9% or lower (≤52 mmol per mole), 2.38 (95% CI, 2.02 to 2.80) for a level of 7.0 to 7.8% (53 to 62 mmol per mole), 3.11 (95% CI, 2.66 to 3.62) for a level of 7.9 to 8.7% (63 to 72 mmol per mole), 3.65 (95% CI, 3.11 to 4.30) for a level of 8.8 to 9.6% (73 to 82 mmol per mole), and 8.51 (95% CI, 7.24 to 10.01) for a level of 9.7% or higher (≥83 mmol per mole). Corresponding hazard ratios for death from cardiovascular causes were 2.92 (95% CI, 2.07 to 4.13), 3.39 (95% CI, 2.49 to 4.61), 4.44 (95% CI, 3.32 to 5.96), 5.35 (95% CI, 3.94 to 7.26), and 10.46 (95% CI, 7.62 to 14.37).
Conclusions: In our registry-based observational study, patients with type 1 diabetes and a glycated hemoglobin level of 6.9% or lower had a risk of death from any cause or from cardiovascular causes that was twice as high as the risk for matched controls. (Funded by the Swedish Society of Medicine and others.).
Comment in
-
Diabetes: Elevated risk of mortality in type 1 diabetes mellitus.Nat Rev Endocrinol. 2015 Mar;11(3):136-8. doi: 10.1038/nrendo.2014.245. Epub 2015 Jan 13. Nat Rev Endocrinol. 2015. PMID: 25583696 No abstract available.
-
Diabetes. Excess mortality in well-controlled T1DM without renal disease.Nat Rev Nephrol. 2015 Mar;11(3):132-4. doi: 10.1038/nrneph.2014.249. Epub 2015 Jan 20. Nat Rev Nephrol. 2015. PMID: 25599623
-
Glycemic control and excess mortality in type 1 diabetes.N Engl J Med. 2015 Feb 26;372(9):880-1. doi: 10.1056/NEJMc1415677. N Engl J Med. 2015. PMID: 25714168 No abstract available.
-
Glycemic control and excess mortality in type 1 diabetes.N Engl J Med. 2015 Feb 26;372(9):879. doi: 10.1056/NEJMc1415677. N Engl J Med. 2015. PMID: 25714169 No abstract available.
-
Glycemic control and excess mortality in type 1 diabetes.N Engl J Med. 2015 Feb 26;372(9):879-80. doi: 10.1056/NEJMc1415677. N Engl J Med. 2015. PMID: 25714170 No abstract available.
-
Glycemic control and excess mortality in type 1 diabetes.N Engl J Med. 2015 Feb 26;372(9):880. doi: 10.1056/NEJMc1415677. N Engl J Med. 2015. PMID: 25714171 No abstract available.
-
[Blood glucose control and mortality in type 1 diabetes].Semergen. 2015 Oct;41(7):397-8. doi: 10.1016/j.semerg.2015.01.006. Epub 2015 Mar 24. Semergen. 2015. PMID: 25816980 Spanish. No abstract available.
Similar articles
-
Excess Mortality among Persons with Type 2 Diabetes.N Engl J Med. 2015 Oct 29;373(18):1720-32. doi: 10.1056/NEJMoa1504347. N Engl J Med. 2015. PMID: 26510021
-
Glycemic Control, Renal Complications, and Current Smoking in Relation to Excess Risk of Mortality in Persons With Type 1 Diabetes.J Diabetes Sci Technol. 2016 Aug 22;10(5):1006-14. doi: 10.1177/1932296816652901. Print 2016 Sep. J Diabetes Sci Technol. 2016. PMID: 27301980 Free PMC article.
-
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes.N Engl J Med. 2017 Apr 13;376(15):1407-1418. doi: 10.1056/NEJMoa1608664. N Engl J Med. 2017. PMID: 28402770
-
Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.Dan Med J. 2018 Apr;65(4):B5454. Dan Med J. 2018. PMID: 29619932 Review.
-
[Risk factors for cardiovascular disease. Results from the Swedish national diabetes register compared with international studies].Lakartidningen. 2013 Apr 24-May 6;110(17-18):882-5. Lakartidningen. 2013. PMID: 23717939 Review. Swedish. No abstract available.
Cited by
-
What is the Relationship Between Time in Range, Time in Tight Range, and HbA1c in Youth and Young Adults With Type 1 Diabetes? Results From the German/Austrian/Luxembourgian/Swiss Diabetes Prospective Follow-Up Registry.J Diabetes Sci Technol. 2024 Nov 16:19322968241288870. doi: 10.1177/19322968241288870. Online ahead of print. J Diabetes Sci Technol. 2024. PMID: 39548894 Free PMC article.
-
Impact of Digitally Enabled Peer Support Interventions on Diabetes Distress and Depressive Symptoms in People Living with Type 1 Diabetes: A Systematic Review.Curr Diab Rep. 2024 Oct 28;25(1):1. doi: 10.1007/s11892-024-01560-4. Curr Diab Rep. 2024. PMID: 39470851
-
Unseen threat: how subclinical atherosclerosis increases mortality risk in patients with type 1 diabetes.Cardiovasc Diabetol. 2024 Oct 17;23(1):366. doi: 10.1186/s12933-024-02455-0. Cardiovasc Diabetol. 2024. PMID: 39420367 Free PMC article.
-
Explainable Machine-Learning Models to Predict Weekly Risk of Hyperglycemia, Hypoglycemia, and Glycemic Variability in Patients With Type 1 Diabetes Based on Continuous Glucose Monitoring.J Diabetes Sci Technol. 2024 Oct 8:19322968241286907. doi: 10.1177/19322968241286907. Online ahead of print. J Diabetes Sci Technol. 2024. PMID: 39377175 Free PMC article.
-
The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes.Metabolites. 2024 Sep 7;14(9):487. doi: 10.3390/metabo14090487. Metabolites. 2024. PMID: 39330494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical